New York, Jan 5, 2026, 14:59 EST — Regular session
Thermo Fisher Scientific Inc shares rose about 2.4% in afternoon trading on Monday after Evercore ISI raised its price target to $650 from $610 and kept an “outperform” rating, a call that signals expectations for the stock to beat the broader market. The stock was last up 2.4% at $606.63, after swinging between $590.00 and $608.29 on volume of about 1.6 million shares. MarketScreener
The move puts Thermo Fisher back on screens ahead of its late-January results, when investors will look for fresh clues on drugmaker and laboratory spending that can ripple across the life-sciences tools group.
Life-sciences tools companies sell lab instruments, diagnostics and consumables. Their guidance often tracks research budgets at pharmaceutical and biotech firms, making the sector a bellwether for deal and funding cycles as earnings season approaches.
Peers also advanced, with Danaher up about 1.9%, Agilent Technologies up about 3.1% and Illumina up about 4.1% in mid-afternoon trade.
The broader market backdrop was supportive, with Wall Street rising after a U.S. strike that captured Venezuelan President Nicolás Maduro lifted energy and financial shares. “The lack of permanent boots on the ground … means the broader equity markets are able to set aside what might have been fears of a prolonged engagement,” said Rob Haworth, senior investment strategist at U.S. Bank Wealth Management. Reuters
For Thermo Fisher, the next report will be watched for demand trends in lab tools and services, including any update on the company’s exposure to China. The company last raised its annual forecasts in October on strong demand for lab tools, even as it pointed to a decline in China.
Investors will also weigh progress on Thermo’s planned acquisition of clinical services provider Clario, a deal the company has said would broaden its footprint in clinical trial support. Thermo agreed in October to buy Clario for up to $9.4 billion, a transaction expected to close in early 2026.
But expectations are rising into earnings, and any miss on margins or a softer tone on customer spending could hit the shares, especially if market volatility returns on geopolitical headlines or rate-sensitive macro data.
Next up for investors is the U.S. employment report for December, due on Jan. 9 at 8:30 a.m. ET, followed by Thermo Fisher’s fourth-quarter and full-year results on Jan. 29 before the market opens, with a conference call at 8:30 a.m. ET.
